Navigation Links
BridgePoint Medical Announced 510(k) Clearance for an Expanded Indication to Treat Coronary Chronic Total Occlusions
Date:5/16/2011

MINNEAPOLIS, May 16, 2011 /PRNewswire/ -- BridgePoint Medical, Inc., a Minnesota-based medical device company, has announced that they have received clearance of an expanded indication for the CrossBoss™ Catheter and Stingray™ System from the FDA.  The expanded indication includes the intraluminal placement of conventional guidewires beyond stenotic coronary lesions [including chronic total occlusions (CTOs)] prior to PTCA or stent intervention.  CTOs are chronically stenosed lesions that completely block a coronary artery – typically for 3 months or longer - and prevent blood circulation to critical areas of the heart.  

Company Founder & COO Chad Kugler reflected, "This is the culmination of 5 years of development, clinical and regulatory work.  We are grateful for the opportunity to market these products for the specific challenge they were developed for and confident that we have created a great solution for treating CTOs."

This expanded indication is the result of data generated from the 147-patient FAST-CTOs clinical trial in which the safety and effectiveness of the system in coronary chronic total occlusions was demonstrated.

Dr. William Lombardi of St. Joseph's Hospital in Bellingham, WA and a leading enroller in the clinical trial states, "The BridgePoint system is the first set of devices designed specifically for treating coronary Chronic Total Occlusions that has shown real improvements in safety, procedural efficiency, and clinical success rates.  The clinical trial has proven that these arteries can be opened effectively with these products and now with the expanded indication from the FDA there will be a new level of awareness among physicians and patients."

BridgePoint's ability to commercialize its CrossBoss™ Catheter and Stingray™ System will be greatly expanded with this new level of indication.  BridgePoint is the first interventional device company to be granted this specific type of approval for both crossing and re-entry technologies to be used in the treatment of coronary CTOs.

Company CEO and President Denis Harrington says, "We are excited about the expanded indication.  The FAST-CTO Trial demonstrated the safety and effectiveness of the CrossBoss Catheter and Stingray System in treating these most challenging lesions – CTOs.  And we are poised to be the leader in helping physicians treat these patients."

About BridgePoint Medical:

BridgePoint Medical, Inc. is a privately held company established in 2006 to design, develop and commercialize new technologies and techniques to treat challenging coronary and peripheral artery disease.  Investors include New Enterprise Associates, Polaris Venture Partners, Foundation Medical Partners and Michael Berman.


'/>"/>
SOURCE BridgePoint Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BridgePoint Medical Names Industry Veteran as Chief Executive Officer
2. BridgePoint Medical Closes $9.1 Million Series C Financing
3. BridgePoint Medical®, Inc. Completes and Submits to FDA in the U.S. FAST-CTOs With the CrossBoss® and Stingray® CTO Recanalization System
4. BridgePoint Medical(R) Receives European CE Mark for Stingray(R) and CrossBoss(TM) for Opening Completely Blocked Arteries
5. UBM Canon Medical Device Content Team Announces Upcoming Virtual Event Content Topics
6. FDA Formally Accepts Dune Medicals MarginProbe™ System Pre-Market Approval (PMA) Application and Grants Expedited Review Status
7. STMicroelectronics Reveals Best-in-Class Technology Enabling Longer-Lasting Broadcast and Medical-Imaging Equipment
8. Reportlinker Adds Impact of Healthcare Reforms on the Medical Technology Industry
9. Winner Medical to Present at Oppenheimer 5th Annual China Dragon Conference
10. Royce Receives Coveted Medical Products Award
11. Medical Care Technologies Inc. Selects Geographical Location for Flagship Childrens Health Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , Deutschland und GERMANTOWN, Maryland ... Zusammenarbeit mit Therawis bedient dringenden ... Brustkrebs   QIAGEN N.V. (NASDAQ: ... heute bekannt, eine Lizenz- und Entwicklungsvereinbarung mit Therawis ... für die Onkologie eingegangen zu sein. Ein erstes ...
(Date:5/25/2016)... 25, 2016 According to market ... Growth and Demand Forecast to 2022 - Industry Insights ... Others)" published by P&S Market Research, the global insulin ... 2015, and it is expected to grow at a ... insulin pump segment is expected to witness the fastest ...
(Date:5/25/2016)... MedDay, a biotechnology company focused on ... presentation entitled "High doses of biotin in progressive multiple sclerosis: ... by Professor Ayman Tourbah , Principal Investigator of the ... Academy of Neurology (EAN) in Copenhagen, Denmark ... take place on Sunday, 29 May 2016 from 14:45 to ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... ... The Bank of America Charitable Foundation has awarded a grant to the General ... employment and successful careers in healthcare. On Wednesday, May 4th, Rick Bridwell, Bank of ... Medisend, parent organization and home of the General Myers Veterans Program. , “The ...
(Date:5/25/2016)... ... ... CloudLIMS, joins an elite number of companies that have earned a spot ... by CIOReview. , In a deliberate session with the honorary industrial experts, a list ... concluded with. The positioning is based on evaluation of CloudLIMS’ specialties in Automated Sample ...
(Date:5/25/2016)... ... May 25, 2016 , ... The Global Wellness Summit ... unique integrative medical wellness offerings of Europe, a continent that pioneered the medical/wellness concept ... hear from numerous pioneers in medical wellness, including Henri Chenot, Founder of the Chenot ...
(Date:5/25/2016)... FRANCISCO, CA (PRWEB) , ... May 25, 2016 , ... ... School of Nursing and Health Professions. She will lead a team of more than ... Team. Baker will begin her role as dean in late August. , Baker comes ...
(Date:5/25/2016)... ... May 25, 2016 , ... BeniComp Insurance Company, a ... in their clients' employee participation for their wellness initiatives. BeniComp clients experience ... high-deductible health plan with outcome-based deductible incentives. As a result, BeniComp clients have ...
Breaking Medicine News(10 mins):